Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
10.43
-0.07 (-0.67%)
Jan 16, 2026, 12:58 PM EST - Market open
DAWN Stock Forecast
Stock Price Forecast
The 9 analysts that cover DAWN stock have a consensus rating of "Strong Buy" and an average price target of $27.56, which forecasts a 164.24% increase in the stock price over the next year. The lowest target is $16 and the highest is $36.
Price Target: $27.56 (+164.24%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DAWN stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Initiates $34 | Strong Buy | Initiates | $34 | +225.98% | Jan 13, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +139.69% | Nov 24, 2025 |
| Needham | Needham | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +53.40% | Nov 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +158.87% | Nov 7, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $25 → $26 | Buy | Maintains | $25 → $26 | +149.28% | Nov 5, 2025 |
Financial Forecast
Revenue This Year
153.88M
from 131.16M
Increased by 17.32%
Revenue Next Year
236.09M
from 153.88M
Increased by 53.42%
EPS This Year
-1.04
from -1.02
EPS Next Year
-0.66
from -1.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 165.4M | 309.8M | ||||
| Avg | 153.9M | 236.1M | ||||
| Low | 144.7M | 182.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 26.1% | 101.3% | ||||
| Avg | 17.3% | 53.4% | ||||
| Low | 10.3% | 18.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.88 | -0.07 | ||||
| Avg | -1.04 | -0.66 | ||||
| Low | -1.18 | -1.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.